



Stockholm, 11 August 2020

PRESS RELEASE

Resolutions from Lipidor's Extraordinary General Meeting

Today, 11 August 2020, Lipidor AB (publ) (the "**Company**" or "**Lipidor**") held an extraordinary general meeting ("**EGM**") in Solna, Sweden. The EGM resolved upon, inter alia, the following resolutions.

Resolution on approval of the Company's subsidiary Emollivet AB's (the "Subsidiary" or "Emollivet") resolution on a new issue of shares

The EGM resolved unanimously to approve the Subsidiary's resolution of 30 June 2020 on a new issue of at most 800 shares in the Subsidiary with deviation from the shareholders' pre-emption rights (the "**New Issue**"). The subscription price amounts to SEK 5,000 per share and Emollivet is provided with SEK 4,000,000 on full subscription. Provided that the New Issue is fully subscribed for, the corresponding dilution effect amounts to approximately 42.1 percent of the total number of shares and votes in Emollivet. Lipidor will own 951 shares in Emollivet after the New Issue corresponding to approximately 50.1 percent of the total number of shares and votes in Emollivet. The resolution was made in accordance with the proposal which was included in the notice convening the EGM and which can be read on the Company's website www.lipidor.se.

Resolution on approval of Emollivet's resolution on a long-term incentive program

The EGM resolved unanimously to approve the Subsidiary's resolution of 30 June 2020 on a new issue of at most 95 warrants of series 2020/2023 in the Subsidiary to the Subsidiary's CEO (the "**Warrant Program**"). Each warrant entitles the holder to subscribe for one new share during the period 11 August 2022 – 11 August 2023 to a price of SEK 10,000 per share. The resolution was made in accordance with the proposal which was included in the notice convening the EGM and which can be read on the Company's website www.lipidor.se.

Upon full subscription and exercising of all warrants the Warrant Program will entail a dilution effect of approximately 7.9 percent of the total current number of shares and votes in Emollivet. If the New Issue is fully subscribed for the dilution effect of the Warrant Program will amount to approximately 4.8 percent of the total number of shares and votes in Emollivet.

For more information, please contact

Fredrik Sjövall, Chairman
Phone: +46 70 645 08 75
E-mail: fredrik.sjovall@lipidor.se

Certified Advisor

Corpura Fondkommission AB
Telephone: +46 76 85 32 822
E-mail: ca@corpura.se

About Lipidor AB

Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.